Your English writing platform
Discover LudwigSimilar(60)
To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate.
Three alternatives of comparison were set: no treatment, real-world persistence, and ideal persistence.
The cost of non-persistence was defined as the difference between total cost of ideal and real-world persistence alternatives.
Costs and events were firstly estimated for three alternatives: no-treatment, real-world persistence, and ideal persistence.
In addition, a better understanding of the real-world persistence of WNV antibodies in live bird surveillance programs would be useful for virus dispersal models.
Compared to no-treatment and real-world persistence alternatives, all proportions of cost ranges over €3,000 decreased in the ideal persistence alternative.
In a context of generic prices, the hypothetical alternative of ideal persistence with oral bisphosphonates was shown economically dominant on the real-world persistence.
Incremental cost-effectiveness ratios (ICERs) were calculated first between real-world adherence and no treatment alternatives, and second between ideal and real-world persistence alternatives.
The real-world persistence alternative assumed all patients were treated by weekly or monthly bisphosphonates and was based on current persistence rates from observational studies.
The cost of non-persistence was defined as the difference between costs balance sheet of ideal and real-world persistence alternatives.
Based on the results of the model, improving persistence with oral bisphosphonates was shown economically dominant on the real-world persistence.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com